Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

509 questions · 514 findings · 44 reviews

No studies found 35 · 6.8%GRADE not reported 31 · 6%Very low 41 · 8%Low 149 · 29%Moderate 196 · 38.1%High 62 · 12.1%

Intermittent 'as needed' ICS vs daily ICS

Patients with serious adverse health events (duration 12 to 52 weeks) · Children and adults with persistent asthma.

Intermittent 'as needed' ICS showed no clear difference in patients with serious adverse health events (duration 12 to 52 weeks) compared with daily ICS (low certainty).

1 finding from 1 review

Intermittent 'as needed' ICS vs daily ICS

Patients with at least 1 exacerbation requiring emergency department/acute care visit (duration 12 to 52 weeks) · Children and adults with persistent asthma.

Intermittent 'as needed' ICS showed no clear difference in patients with at least 1 exacerbation requiring emergency… compared with daily ICS (low certainty).

1 finding from 1 review

Intermittent 'as needed' ICS vs daily ICS

Change from baseline AM PEFR (%) (duration 44 to 52 weeks) · Children and adults with persistent asthma.

Intermittent 'as needed' ICS showed no clear difference in change from baseline AM PEFR (%) (duration 44 to 52 weeks) compared with daily ICS (moderate certainty).

1 finding from 1 review

Intermittent 'as needed' ICS vs daily ICS

Change from baseline mean daily use of β2‐agonists (puffs/day) (duration 24 to 44 weeks) · Children and adults with persistent asthma.

Intermittent 'as needed' ICS showed no clear difference in change from baseline mean daily use of β2‐agonists (puffs/day)… compared with daily ICS (moderate certainty).

1 finding from 1 review